Cotylenin A and arsenic trioxide cooperatively suppress cell proliferation and cell invasion activity in human breast cancer cells

International Journal of Oncology

Volumn 46, Issue 2, 2015, Pages 841-848

  Kasukabe, Takashi ^a,b   Okabe Kado, Junko ^b   Kato, Nobuo ^c   Honma, Yoshio ^a   Kumakura, Shunichi ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b SAITAMA CANCER CENTER   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Arsenic trioxide; Breast cancer cells; Cotylenin A; Invasion activity; Proliferation

Indexed keywords

ACETYLCYSTEINE; ANTIMITOTIC AGENT; ARSENIC TRIOXIDE; CASPASE 7; COTYLENIN A; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DEATH RECEPTOR 5; FAS ANTIGEN; HYDROGEN PEROXIDE; ISIR 005; PHYTOHORMONE; SEPANTRONIUM BROMIDE; SURVIVIN; UNCLASSIFIED DRUG; DITERPENE; ORGANOARSENIC DERIVATIVE; OXIDE;

ANCHORAGE INDEPENDENT GROWTH; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LOW DRUG DOSE; MCF 7 CELL LINE; PROTEIN EXPRESSION; BREAST NEOPLASMS; CELL CYCLE; CELL DIFFERENTIATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; TUMOR INVASION;

APOPTOSIS; ARSENICALS; BREAST NEOPLASMS; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; DITERPENES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; NEOPLASM INVASIVENESS; OXIDES;

EID: 84918495759     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2760     Document Type: Article

References (40)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Siegel R, Naishadham MA and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
3. Hurvitz S, Hu Y, O'Brien N and Finn RS: Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev 39: 219-229, 2013.
4. Gianni M, Koken MH, Chelbi-Alix MK, Benoit G, el al: Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 91: 4300-4310, 1998.
5. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354-3360, 1997.
6. Deuer D and Tallman MS: Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 23: 2396-2410, 2005.
7. Platanias L: Biological responses to arsenic compounds. J Biol Chem 284: 18583-18587, 2009.
8. Emadi A and Gore SD: Arsenic trioxide-An old drug rediscovered. Blood Rev 24: 191-199, 2010.
9. Takahashi S: Combination therapy with arsenic trioxide for hematological malignancies. Anticancer Agents Med Chem 10: 504-510, 2010.
10. Zhang X, Su Y and Sun Z: Opposite effects of arsenic trioxide on the Nrf2 pathway in oral squamous cell carcinoma in vitro and in vivo. Cancer Lett 18: 93-98, 2012.
11. Kryeziu K, Jungwirth U, Hoda MA, el al: Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair. Mol Cancer Ther 12: 1073-1084, 2013.
12. Liu W, Gong Y, Li H, el al: Arsenic-induced growth arrest of breast cancer MCF-7 cells involving FOXO3a and IkB kinase β expression and localization. Cancer Biother Radiopharm 27: 504-512, 2012.
13. Kasukabe T, Okabe-Kado J, Haranosono Y, Kato N and Honma Y: Inhibition of rapamycin-induced Akt phosphorylation by cotylenin A correlated with their synergistic growth inhibition of cancer cells. Int J Oncol 42: 767-775, 2013.
14. Vuky J, Yu R, Schwartz L and Motzer RJ: Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Invest New Drugs 20: 327-330, 2002.
15. Kim KB, Bedikian AY, Camacho LH, Papadopoulos NE and McCullough C: A phase II trial of arsenic trioxide in patients with metastatic melanoma. Cancer 104: 1687-1692, 2005.
16. Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL and Yang CH: Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Invest New Drugs 25: 77-84, 2006.
17. Abe O, Abe R, Enomoto K, el al: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365: 1687-1717, 2005.
18. Zhao XY, Yang S, Chen YR, Li PC, Dou MM and Zhang J: Resveratrol and arsenic trioxide act synergistically to kill tumor cells in vitro and in vivo. PloS One 9: e98925, 2014.
19. Sassa T, Tojyo T and Munakata K: Isolation of a new plant growth substance with cytokinin-like activity. Nature 227: 379, 1970.
20. Asahi K, Honma Y and Hazeki K: Cotylenin A, a plant-growth regulator, induces the differentiation in murine and human myeloid leukemia cells. Biochem Biophys Res Commun 238: 758-763, 1997.
21. Yamamoto-Yamaguchi Y, Yamada K, Ishii Y, Asahi KI, Tomoyasu S and Honma Y: Induction of the monocytic differentiation of myeloid leukemia cells by cotylenin A, a plant growth regulator. Br J Haematol 112: 697-705, 2001.
22. Yamada K, Honma Y, Asahi KI, Sassa T, Hino KI and Tomoyasu S: Differentiation of human acute myeloid leukemia cells in primary culture in response to cotylenin A, a plant growth regulator. Br J Haematol 114: 814-821, 2001.
23. Honma Y: Cotylenin A: a plant growth regulator as a differentiation-inducing agent against myeloid leukemia. Leuk Lymphoma 43: 1169-1178, 2002.
24. Yamamoto-Yamaguchi Y, Okabe-Kado J, Kasukabe T and Honma Y: Induction of differentiation of human myeloid leukemia cells by immunosuppressant macrolides (rapamycin and FK506) and calcium/calmodulin-dependent kinase inhibitors. Exp Hematol 29: 582-588, 2001.
25. Kasukabe T, Okabe-Kado J, Kato N, Sassa T and Honma Y: Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts. Breast Cancer Res 7: R1097-R1110, 2005.
26. Kasukabe T, Okabe-Kado J and Honma Y: Cotylenin A, a new differentiation inducer, and rapamycin cooperatively inhibit growth of cancer cells through induction of cyclin G2. Cancer Sci 99: 1693-1698, 2008.
27. Kawakami K, Hattori M, Inoue T, et al: A novel Fusicoccin derivative preferentially targets hypoxic tumor cells and inhibits tumor growth in xenografts. Anticancer Agents Med Chem 12: 791-800, 2012.
28. Nakamaki T, Okabe-Kado J, Yamamoto-Yamaguchi Y, el al: Role of MmTRA1b/phospholipid scramblase 1 gene expression in the induction of differentiation of human myeloid leukemia cells into granulocytes. Exp Hematol 30: 421-429, 2002.
29. Hagiwara Y, Kasukabe T, Kaneko Y, Niitsu N and Okabe-Kado J: Ellagic acid a natural compound, induces apoptosis and potentiates retinoic acid-induced differentiation of human leukemia HL-60 cells. Int J Hematol 92: 136-143, 2010.
30. 3) in endometrial carcinoma cells. Gynecol Oncol 105: 218-222, 2007.
31. Kumar P, Gao Q, Ning Y, Wang Z, Krebsbach PH and Polverini PJ: Mol Cancer Ther 7: 2060-2069, 2008.
32. Feng Y, Pan TC, Pant DK, el al: SPSB1 promotes breast cancer recurrence by potentiating c-MET signaling. Cancer Discov 4: 790-803, 2014.
33. Janicke RU, Sprenger ML, Wati MR and Porter AG: Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273: 9357-9360, 1998.
34. Aziz MY, Omar AR, Subramani T, et al: Damnacanthal is a potent inducer of apoptosis with anticancer activity by stimulating p53 and p21 genes in MCF-7 breast cancer cells. Oncol Lett 7: 1479-1484, 2014.
35. Shin S, Sung BJ, Cho YS, et al: An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40: 1117-1123, 2001.
36. Nakahara T, Takeuchi M and Kinoyama I, et al: YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 67: 8014-8021, 2007.
37. Li W, Wang M, Wang L, Ji S, Zhang J and Zhang C: Icariin synergizes with arsenic trioxide to suppress human hepatocellular carcinoma. Cell Biochem Biophys 68: 427-436, 2014.
38. Nakaoka T, Ota A, Ono T, et al: Combined arsenic trioxidecisplatin treatment enhances apoptosis in oral squamous cell carcinoma cells. Cell Oncol 37: 119-129, 2014.
39. Limame R, Wouters A, Pauwels B, et al: Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays. PloS One 7: e46536, 2012.
40. Si L, Jiang F, Li Y, et al: Induction of the mesenchymal to epithelial transition by demethylation-activated microRNA-200c is involved in the anti-migration/invasion effects of arsenic trioxide on human breast cancer cells. Mol Carcinog: Apr 14, 2014. doi: 10.1002/mc.22157. (Epub ahead of print).